microdosing semaglutide People are 'microdosing' weight-loss drugs. A GP explains what to watch out for Microdosing GLP-1s: Safety, Dosage, Side

In a 68- and 72-week clinical trial studying Wegovy (2.4 mg) and Zepbound (15 mg) in patients without diabetes and with BMI 30, or BMI 27 with a weight-related condition, the average weight loss was 15% and 20%, when paired with diet and exercise changes (compared to 2.4% and 3.1%, respectively, with diet and exercise alone)

If using a syringe, pinch the skin slightly, insert the needle, and press the plunger

Yes we provide mobile treatments across Sydney for IV Therapy, servicing homes, hotels, and offices

Belmont-Rausch DM et al

Reducing BMI below the obesity threshold in adolescents treated with once-weekly subcutaneous semaglutide 2.4 mg

The approach can look different for people taking it for weight loss versus diabetes or heart health